Last reviewed · How we verify

Vascular Solutions LLC — Portfolio Competitive Intelligence Brief

Vascular Solutions LLC pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fresh Frozen Plasma (FFP) Fresh Frozen Plasma (FFP) marketed Blood product / Plasma derivative Hematology / Hemostasis

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Baxter Healthcare Corporation · 1 shared drug class
  2. Coalition for National Trauma Research · 1 shared drug class
  3. Erasmus Medical Center · 1 shared drug class
  4. Rigshospitalet, Denmark · 1 shared drug class
  5. Rutgers, The State University of New Jersey · 1 shared drug class
  6. Vastra Gotaland Region · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vascular Solutions LLC:

Cite this brief

Drug Landscape (2026). Vascular Solutions LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vascular-solutions-llc. Accessed 2026-05-17.

Related